Polish Court Enforces CIETAC Arbitration Award Against Bioton
Stories are grouped across languages, rewritten into a fixed editorial format, and linked to original sources. How we report.
TL;DR
- Warsaw Court of Appeal recognized and enforced a Chinese CIETAC arbitration award against Bioton.
- The dispute concerns contractual settlements from a 2011 agreement involving Bioton, SciGen, and Chinese entities.
- Bioton must pay $1.5 million, plus interest and costs, to Hefei Life Science Park Investments and Development.
- The decision is final, though Bioton may seek further legal remedies.
Overview
On 26 May 2026, the Warsaw Court of Appeal recognized and declared enforceable a 2017 CIETAC arbitration award ordering Bioton and its partner SciGen to pay significant sums to Hefei Life Science Park Investments and Development. The underlying matter centers on a long-running dispute regarding contractual settlements and licensing payments arising from a 2011 agreement. The court's decision is final but may be subject to further appeal.
What Happened
The Warsaw Court of Appeal ruled on an application to recognize and enforce a CIETAC (China International Economic and Trade Arbitration Commission) award from 2017. The award ordered Bioton and SciGen to pay Hefei Life Science Park Investments and Development approximately $1.5 million in damages, interest from 2015 at a daily rate of 0.05%, $146.80 in licensing fees, and additional arbitration-related costs.
Bioton had argued that the claims were time-barred and that Chinese procedural deadlines for enforcement had expired in 2019, presenting a legal opinion to that effect. However, the court found no grounds to refuse recognition or enforcement under the 1958 New York Convention. It dismissed a motion for a Chinese law expert, finding it unnecessary.
The court emphasized that documents supporting the application were complete and that the Chinese arbitration award had not been set aside at the place of arbitration. The court further clarified that Chinese enforcement deadlines do not apply in Poland.
The ruling is final as of its announcement. However, Bioton may file an extraordinary appeal to the Supreme Court and is currently considering further legal action.
Context
The dispute originates from a 2011 contract among Bioton, SciGen Ltd., Hefei Life Science Park, and Gao Xiaoming, relating to their joint cooperation and associated licensing and financial obligations.
Bioton specializes in biotechnological and pharmaceutical products and has been listed on the Warsaw Stock Exchange since 2005. This enforcement action follows years of dispute over settlement of these obligations.
Why It Matters
- The case highlights cross-border enforcement of arbitral awards in the EU under the New York Convention.
- It demonstrates the obstacles debtors face when seeking to resist recognition on grounds related to foreign law or procedural time limits.
- The decision reinforces the ability of foreign investors to pursue enforcement of arbitral awards through Polish courts.